Intra-Cellular Therapies Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Intra-Cellular Therapies's estimated annual revenue is currently $9.2M per year.
- Intra-Cellular Therapies received $150.0M in venture funding in September 2017.
- Intra-Cellular Therapies's estimated revenue per employee is $27,035
- Intra-Cellular Therapies's total funding is $20.9M.
- Intra-Cellular Therapies has 342 Employees.
- Intra-Cellular Therapies grew their employee count by 302% last year.
- Intra-Cellular Therapies currently has 7 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Intra-Cellular Therapies?
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities: https://www.linkedin.com/jobs/search/keywords=intra-cellular%20therapies&location=United%20States&locationId=us%3A0keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Intra-Cellular Therapies News
The Food and Drug Administration told Intra-Cellular Therapies (NASDAQ:ITCI) that it doesn't plan to hold an advisory committee meeting to ...
Intra-Cellular Therapies is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the ...
The FDA has informed Intra-Cellular Therapies (NASDAQ:ITCI) that it has no plans to schedule an Advisory Committee meeting regarding the ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Intra-Cellular Therapies Funding
|2014-02-03||$100.2M||Undisclosed||Leerink Partners LLC||Article|
|2014-02-06||$115.3M||Undisclosed||Leerink Partners LLC||Article|
|2015-03-09||$106.5M||Undisclosed||Leerink Partners LLC||Article|
|2015-03-13||$121.4M||Undisclosed||Leerink Partners LLC,||Article|
|2017-09-29||$150.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
Intra-Cellular Therapies Executive Hires
|2014-03-11||Juan Sanchez||VP Corporate Communications/Investor Relations||Article|
|2018-08-21||Suresh Durgam||SVP Late Stage Clinical Development & Medical Affairs.||Article|
|2018-09-26||Michael Olchaskey||SVP/Head of Regulatory Affairs||Article|